<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986385</url>
  </required_header>
  <id_info>
    <org_study_id>HRA-G04</org_study_id>
    <nct_id>NCT03986385</nct_id>
  </id_info>
  <brief_title>Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction</brief_title>
  <official_title>Prospective, Randomized, Controlled, Multicenter, Phase III Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of patients who receive
      concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2
      negative adenocarcinoma at gastroesophageal junction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The pathological complete response rate(pCR)</measure>
    <time_frame>[ Time Frame: within 3 weeks after surgery ]</time_frame>
    <description>The lesion disappeared completely by pathology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival(DFS)</measure>
    <time_frame>[ Time Frame: 3 year ]</time_frame>
    <description>Baseline to measured date of recurrence or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>[ Time Frame: Preoperative ]</time_frame>
    <description>Baseline to measured stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate（DCR）</measure>
    <time_frame>[ Time Frame: Preoperative ]</time_frame>
    <description>Baseline to measured disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0-resection rate</measure>
    <time_frame>[ Time Frame: within 3 weeks after surgery ]</time_frame>
    <description>There was no residual by the microscope</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>[ Time Frame: 3years ]</time_frame>
    <description>Baseline to measured date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>A(apatinib Xelox)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative: apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 2 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B(Xelox)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Capecitabine Oxaliplatin</intervention_name>
    <description>apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w</description>
    <arm_group_label>A(apatinib Xelox)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine Oxaliplatin</intervention_name>
    <description>Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w</description>
    <arm_group_label>B(Xelox)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients (18 to 70 years old) at the time of voluntarily signing informed
             consent;

          2. Histologically or cytologically confirmed adenocarcinoma. The her-2 negative was
             detected by immunohistochemistry or fluorescence in situ hybridization;

          3. Conﬁrmed to Siewert II , III of locally advanced adenocarcinoma at gastroesophageal
             junction and tumor long diameter ≤8 cm by gastroscopy;

          4. Patients with Stage for Ⅲ by CT/MRI (According to the eighth edition of AJCC );

          5. Patients with measurable lesions(measuring≥10mm on spiral CT scan, satisfying the
             criteria in RECIST1.1);

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

          7. Life expectancy greater than or equal to 6 months;

          8. Subject must meet all of the following criteria based on the laboratory tests within
             14 days prior to the first dose of study treatment.

        (1) Baseline blood indicators meet the following
        criteria:HB≥80g/L;ANC≥1.5×109/L;PLT≥90×109/L;WBC≥4.0×109/L and ≤15×109/L (2) Baseline
        biochemical indicators meet the following criteria: ALT and AST≤2.5ULN, but&lt;≤5ULN if the
        transferanse elevation is due to liver metastases;
        ALP≤2.5ULN;TBiL≤1.5ULN；Cr≤1.5ULN,Endogenous creatinine clearance rate ˃60 ml/min
        (Cockcroft-Gault formula);APTT≤1.5ULN,and INR or PT≤1.5ULN.

        9.Women of childbearing age must have contraceptive measures or have test pregnancy (serum
        or urine) enroll the study before 7 days, and the results must be negative, and take the
        methods of contraception during the test and the last to have drugs after 8 weeks. Men must
        be contraception or has sterilization surgery during the test and the last to have drugs
        after 8 weeks; 10.Participants were willing to join in this study, and written informed
        consent, good adherence, cooperate with the follow-up.

        Exclusion Criteria:

          1. Allergic to apatinib, capecitabine and oxaliplatin;

          2. The cytological examination of the abdominal cavity washing fluid showed that the
             tumor shedding cells were positive;

          3. Have high blood pressure and antihypertensive drug treatment can not control (systolic
             blood pressure &gt; 140 mmHg,diastolic blood pressure &gt; 90 mmHg),Uncontrolled coronary
             heart disease and arrhythmia,classⅢ-Ⅳcardiac insufficiency;

          4. A variety of factors influencing oral drugs (such as unable to swallow,
             nausea,vomiting,chronic diarrhea and intestinal obstruction, etc);

          5. Patients with tendency of gastrointestinal bleeding, including the following:a local
             active ulcerative lesions,and defecate occult blood;Has melena and hematemesis in two
             months;

          6. Coagulant function abnormality (INR &gt; 1.5 ULN, APTT &gt; 1.5 ULN), with bleeding
             tendency;

          7. Pregnant or lactating women;

          8. Patients with other malignant tumors within 5 years (except for curable skin basal
             cell carcinoma and cervical carcinoma in situ);

          9. History of psychiatric drugs abuse and can't quit or patients with mental disorders;

         10. Less than 4 weeks from the last clinical trial;

         11. The researchers think inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>QunZhao</name>
      <address>
        <city>Shijia Zhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qun Zhao</last_name>
      <phone>8613930162111</phone>
      <email>zhaoqun@hebmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Qun Zhao</investigator_full_name>
    <investigator_title>Surgical director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

